The test is covered for serial use in patients with colorectal cancer in the adjuvant and recurrence monitoring settings over a five-year period.

The firms will distribute NowDx's First to Know test to more than 15 organizations nationwide, including LGBTQ+ health centers, HIV/AIDS care providers, and safety net clinics.

The acquisition was opposed by some Quanterix shareholders. In May, Akoya also said it received an unsolicited acquisition bid for the firm.

NEW YORK — Laboratory Corporation of America and NowDiagnostics (NowDx) said Tuesday that they have launched an initiative to distribute NowDx's First to Know Syphilis test at no cost to ...

The Tulane team has developed a handful of other assays for TB detection, including a mass spec test for paucibacillary TB ...

The test is used for the detection of antibodies against Borrelia burgdorferi in serum from patients with signs, symptoms, and clinical history consistent with Lyme disease.

Cardio Dx will sponsor a clinical study investigating use of its PrecisionCHD test to identify patients with CHD and assess response to Agepha's low-dose colchicine agent LODOCO.

The acquired antibodies target hormones like thyroid stimulating hormone, human chorionic gonadotropin, prolactin, and total thyroxine.

Investigators compared risk prediction using PathomIQ's platform to molecular test results, evaluating its ability to predict biochemical recurrence in high-risk patients.

Broader macroeconomic uncertainty has resulted in continued cautiousness for both investors and acquirers in the in vitro ...

Last week, readers were most interested in a story about Diasorin's submission to the FDA for its POC testing instrument.

Health Canada has allowed the firm to bypass a requirement that tests be authorized for non-professional use prior to self-test authorization.